Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology
September 27, 2023 08:30 ET
|
Zylö Therapeutics
Z-pods significantly improved outcomes in mouse model of cutaneous lupus GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
How Indian outsourcing industry is moving up the value chain - Article published in TOI
December 28, 2022 10:00 ET
|
Integra Global Solutions
Pittsburgh, PA, Dec. 28, 2022 (GLOBE NEWSWIRE) -- We are excited to announce that Ganesh Ranganathan, Chairman, and CEO of Integra Global Solutions’ article has been published in the Voices segment...
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
July 12, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their...
LiveCare Inc. Published PCAOB Audit For Fiscal Year 2021; Validates Proof of Concept
June 01, 2022 11:18 ET
|
LiveCare Inc.
Venice, FL USA, June 01, 2022 (GLOBE NEWSWIRE) -- LiveCare Inc. OTC:(LVCE), With the completion of its fiscal year 2021 PCAOB audit, validates its proof of concept as an innovative leader in the...
COLORESCIENCE® REVEALS CLINICAL STUDY RESULTS OF THE FINISHING TOUCH™ SKINCARE PROTOCOL FOLLOWING FACIAL RADIOFREQUENCY MICRONEEDLING PROCEDURES
May 25, 2022 08:45 ET
|
Colorescience
Carlsbad, CA, May 25, 2022 (GLOBE NEWSWIRE) -- In the midst of Skin Cancer Awareness Month, Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company announces...
Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)
October 30, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today a new peer reviewed publication entitled, "The Quest for...
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
August 04, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
April 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...